The use of magnetically driven nanorobots to transport and activate chemotherapeutic prodrugs presents a promising targeted cancer therapy approach that has the potential to minimize many of the negative side effects of current state-ofthe art chemotherapy treatments. In this work, we propose a hybrid nanowire for targeted bioorthogonally driven activation of the latent chemotherapeutic prodrug 5-fluoro-1-propargyl-uracil (Pro-5-FU) in in vitro and in vivo cancer models. 
nanotechnology, nanorobotics, and bioorthogonal activation of latent prodrugs as an efficient alternative to conventional chemotherapy approaches.
Introduction
Tremendous research in the field of cancer therapy has opened up new avenues for treating this devastating disease. [1] In general, the main goal of cancer treatment is to deliver high-doses of antitumor agents to the site of action, while minimizing side effects within the healthy surrounding tissue. [2] A majority of current clinical chemotherapy approaches distribute chemotherapeutic agents throughout the entire body. These treatments lack target specificity and are primarily limited by the reduced target drug-concentration and non-targeted-tissue distribution. [3] These shortcomings render current treatment methods prone to cause fatal side effects for the patients. [4] Further limitations are the fast deactivation, unfavorable pharmacokinetics, and early clearance of the anticancer drug from the body. [5, 6] A promising path to overcome these problems can be obtained from the progress made in the field of nano-biotechnology, by tailoring advanced nanomaterials to allow for site-specific targeting and on-demand drug activation. [7] One approach to restore the clinical use of promising anticancer drugs, with limited pharmacokinetic profiles, is to transform chemotherapeutic agents into latent prodrugs, which are only medically effective upon catalytic activation. [8] This strategy has led in the past to clinical trials and approvals of conventionally unfavorable anticancer drugs. [9, 10, 11] Initially, the activation of bio-labile prodrug systems was dependent on a metabolic activation via enzymes in the organism. However, this approach requires either a change in the metabolic environment of the host by artificially introducing enzymes in the body, or lacks target specificity due to the non-specific abundance of this enzyme throughout the whole organism. [12] A second class of prodrugs, so called the bioorthogonal prodrugs, are inspired by the work of Bertozi et al. on copper free azide-alkyne cycloaddition and Staudinger ligation. [13] Bioorthogonal prodrugs are physiologically stable precursors, which can be activated through biocompatible heterogeneous catalysts by means of bioorthogonal organometallic (BOOM) reactions. [14] Novel strategies are currently focused on transition metals as catalysts for BOOM reactions, such as copper (I), ruthenium (II), and rhodium (II). However, only a few known reactions are suitable to work under physiological conditions without causing toxic side effects. [15, 16, 17] Palladium (Pd), being biocompatible [18, 19, 20] and exhibiting strong catalytic activity, is a promising transition metal candidate for bioorthogonal reactions. [21] Recent research by Weiss et al. demonstrated the spatially-defined Pd mediated bioorthogonal activation of 5-fluoro-1-propagyluracil (Pro-5-FU) and Npropargyloxycarbonylgemcitabine prodrugs to their respective anticancer agents 5-fluorouracil (5-FU) and gemcitabine. [22, 23] Although the prodrugs were biologically inert, their activation by Pd particles embedded in a matrix of glycol-polystyrene resin was sufficient to deprotect the respective propargyl group and restore cytotoxicity and anti-proliferative properties. In this context, intratumoral implants loaded with Pd nanoparticles have been successfully used as bioorthogonal catalysts in in vitro cancer models and in vivo zebrafish. However, further in vivo demonstrations, particularly in mammalian model systems, are crucial to assess the actual therapeutic potential with regards to safety and pharmacological profiles. Furthermore, it is desirable to explore other means of device design to administer the transition metal Pd, directly to the tumor site, to render it minimally invasive.
The use of nanorobots for targeted drug delivery has tremendously impacted the field of medical research within the last decades. [24, 25] Nanorobots have potential benefits over current state-of-the-art medical procedures, such as: (i) targeted drug delivery with increased bioavailability; (ii) reduced human error through computer controlled automated delivery processes; (iii) minimally-invasive remote access inside the body; (iv) minimization of undesired side effects; (v) early diagnosis; and (vi) constant monitoring. [26, 27] Recently, the scientific focus has been on the development of smart micro-and nanorobots to transport and deliver pharmaceutical agents to the respective target site. Various manipulation techniques (light, electromagnetic fields, acoustic waves) together with chemical or biological targeting agents further enhanced the target specificity of such devices in vitro and in vivo. [28, 29, 30, 31, 32] The main challenges of these small-scale robots are still related to the transport of pharmacologically sufficient concentrations of the drug to the target site and the implementation of an efficient remote control release mechanism, exclusively at the region of interest. [33] In this work, we report for the first time, a FePd nanorobot that is capable to target specific sites in the cancer cell population and perform bioorthogonal 
Results and Discussion
The use of nanorobots in biomedical applications demands an assembly strategy that allows for reliable and controlled batch-fabrication of the device. The 
Therefore, the addition of complexing agents is needed in order to bring the standard potentials of both metals closer together and to avoid further redox reactions and precipitation of the constituents in the electrolyte. It has been reported that ammonia sulfate and ammonia citrate are effective stabilizing agents, which prevent ferric hydroxide precipitation and further reduce the noble standard potential of Pd according to the following reactions [34, 35] :
Subsequently, the electrolyte bath was prepared by forming this tetraamine palladium (II) chloride complex by adding ammonia sulfate at a pH of 1 until all of the Pd was dissolved. Afterwards, ammonium citrate dibasic was added to allow the introduction of FeCl3 salts. Next, after vigorous stirring for 2 h, we received a clear solution and used ammonium hydroxide to increase the pH value to 9. The resulting electrolyte bath (Table S1) Next, we assessed the biomedical applicability of our fabricated FePd nanowires as a catalyst for the bioorthogonal prodrug activation in vitro. For the purpose of this work, we have chosen MDA-MB-231 breast cancer cell line, since breast cancer is a highly heterogeneous disease, which represents the most commonly diagnosed and second leading cause of death in women in the western hemisphere. [36] MDA-MB-231 cell line was derived from a metastatic pleural effusion of a breast cancer patient and has been extensively studied for in vitro and in vivo experiments. A scheme of action of the proposed system is represented in Figure 2a . Upon application of the biochemically inert prodrug 5-fluoro-1-propargyl-uracil (Pro-5-FU), no effect on an in vitro breast cancer model (MDA-MB-231) is observed. However, the introduction of the FePd nanorobots is expected to catalyze the bioorthogonal deprotection of Pro-5 FU by cleaving off the attached propargyl group. The resulting biochemically active 5-FU anticancer agent will then enter the cancer cell, followed by its conversion to the active metabolite by deoxyuridine monophosphate induced apoptosis. In the following experiment, the colorimetric MTT assay was used for the quantification of metabolic activity that corresponds to cell viability.
Pd is already an established and proven biocompatible material frequently used in implantable medical devices. [37] However, the biocompatibility of electrodeposited Fe nanowires is somewhat controversial. [38, 39] Hence, before testing the functionality of our FePd nanowires, it was pivotal to determine the biocompatibility of the electrodeposited FePd nanorobots towards cancer and noncancerous cell lines. be attributed to the short time frame of the experiment, since previous studies reported only significant long-term side effects in vivo. [40, 41] The results were also validated histologically, where no differences between the liver and kidney tissue of the animal groups was observed ( Figure S6 ; Figure S7 ). 
Conclusion
In this work, we combined for the first time a magnetically driven, noncytotoxic nanorobot for the bioorthogonal activation of the chemotherapeutic prodrug 
